Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination supplement containing beta-carotene, vitamin C (ascorbic acid), vitamin E (dl-alpha tocopheryl acetate), and zinc (usually as zinc oxide). It is best known as the original Age-Related Eye Disease Study (AREDS) formulation. The primary mechanism of action is antioxidant activity—these ingredients help neutralize free radicals and reduce oxidative stress in tissues. Zinc also plays a role in immune function and cellular metabolism. The AREDS clinical trials demonstrated that this combination can reduce the risk of progression to advanced age-related macular degeneration (AMD) in individuals at moderate to high risk[1][4]. It has also been studied for potential effects on cancer prevention, but evidence outside AMD prevention is limited or inconclusive[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on beta-carotene + vitamin C + vitamin E + zinc.